新曼彻斯特评分系统对早期非小细胞肺癌患者术后预后的评估价值

Prognostic efficacy of new manchester score system(NMSS)in patients with early non-small-cell lung cancer(NSCLC)after surgery

目的:探讨术前曼彻斯特评分系统(NMSS)对非小细胞肺癌(NSCLC)患者术后预后的评估价值。方法:本研究纳入2015年12月至2018年12月在河南省胸科医院确诊为早期NSCLC并进行手术切除的患者共278例。NMSS评分系统根据乳酸脱氢酶(LDH)、碱性磷酸酶(ALP)、血钠、血碳酸氢盐、分期和卡式评分(KPS)分为良好、中等和不良三组,分析NMSS不同分组以及其他临床指标与术后生存时间之间的关系。结果:278例NSCLC患者中,46例(16.5%)为中等组,70例(25.2%)为不良组,高龄、晚期、未接受放化疗与预后相关,NMSS评分为不良组是预后差的独立危险因素。结论:术前高NMSS评分是影响非小细胞肺癌术后预后的独立危险因素,NMSS评分高提示预后不良。在进行非小细胞肺癌治疗相关选择时,可根据患者的辅助检查结果进行相应的预测评估。

Objective:To investigate the prognostic value of preoperative new manchester score system(NMSS)in patients with non-small cell lung cancer(NSCLC)after surgery.Methods:A total of 278 patients who underwent surgical resection of early NSCLC at Henan provincial chest hospital from December 2015 to December 2018 were enrolled.All enrolled patients were divided into three groups according to NMSS,which was determined by lactate dehydrogenase(LDH),alkaline phosphatase(ALP),serum sodium,blood bicarbonate,tumor stages and karnofsky performance status(KPS).The relationship between NMSS and other clinical indicators with postoperative survival time was analyzed.Results:The 278 patients with NSCLC,46(16.5%)were in the median group and 70(25.2%)were in the poor group.The older age,advanced stages,and without chemoradiotherapy were associated with prognosis.Patients in the NMSS poor group was an independent risk factor for poorer prognosis.Conclusion:Preoperative high NMSS score is an independent risk factor for the prognosis of non-small cell lung cancer.In the treatment of non-small cell lung cancer,the corresponding predictive evaluation can be carried out according to the patient's auxiliary examination results.